Houpe D, Peltier M, Cohen-Solal A, Béguin M, Lévy F, Slama M, Chapelain K, Tribouilloy C
Department of Cardiology, South Hospital, Amiens, France.
Int J Cardiol. 2005 Sep 1;103(3):286-92. doi: 10.1016/j.ijcard.2004.08.060.
The treatment of heart failure (HF) due to left ventricular systolic dysfunction has been defined in recent guidelines, but these guidelines are not always applied in routine clinical practice. One of the objectives of the ETICS study was to evaluate medical treatment at discharge and after 1 year in patients hospitalised for a first episode of congestive HF due to left ventricular systolic dysfunction in 2000.
One hundred and seventy nine patients (63% males, mean age of 69+/-13 years) with an ejection fraction < or = 40% were prospectively included. The main aetiology was ischaemic heart disease (44%).
The drugs prescribed at discharge and at one year, respectively, were loop diuretics in 95% and 91% of cases, angiotensin-converting enzyme (ACE) inhibitors in 82% and 75%, spironolactone in 35% and 37%, beta-blockers in 25% and 41%, digitalis glycosides in 34% and 30% of cases, and nitrates in 20% and 16% of cases. ACE inhibitors were prescribed at discharge and at 1 year at dosages reaching 64+/-29% and 72+/-30% of the recommended doses, respectively, and beta-blockers were prescribed at 26+/-16% and 35+/-25% of recommended doses, respectively.
Diuretics and ACE inhibitors are largely prescribed in HF due to left ventricular systolic dysfunction, followed by spironolactone. Beta-blockers are still underused both in terms of the rate of patients receiving them and the daily doses. These results highlight the value of continuing to widely circulate official practice guidelines in order to improve the management of HF due to left ventricular systolic dysfunction.
近期指南已明确了因左心室收缩功能障碍导致的心力衰竭(HF)的治疗方法,但这些指南在日常临床实践中并非总能得到应用。ETICS研究的目标之一是评估2000年因左心室收缩功能障碍首次发作充血性HF而住院的患者出院时及1年后的药物治疗情况。
前瞻性纳入179例射血分数≤40%的患者(63%为男性,平均年龄69±13岁)。主要病因是缺血性心脏病(44%)。
出院时和1年时分别开具的药物中,95%和91%的病例使用了袢利尿剂,82%和75%的病例使用了血管紧张素转换酶(ACE)抑制剂,35%和37%的病例使用了螺内酯,25%和41%的病例使用了β受体阻滞剂,34%和30%的病例使用了洋地黄苷,20%和16%的病例使用了硝酸盐。出院时和1年时开具的ACE抑制剂剂量分别达到推荐剂量的64±29%和72±30%,β受体阻滞剂的剂量分别为推荐剂量的26±16%和35±25%。
在因左心室收缩功能障碍导致的HF中,利尿剂和ACE抑制剂的处方率很高,其次是螺内酯。β受体阻滞剂在接受治疗的患者比例和每日剂量方面仍未得到充分使用。这些结果凸显了持续广泛传播官方实践指南以改善因左心室收缩功能障碍导致的HF管理的价值。